Experienced in Prader-Willi Syndrome

Hideaki Shiraishi

Tochigi, JP 
Experienced in Prader-Willi Syndrome
Tochigi, JP 
OverviewLocationsClinical Research

Overview

Hideaki Shiraishi practices in Tochigi, Japan. Shiraishi is rated as an Experienced expert by MediFind in the treatment of Prader-Willi Syndrome. Their top areas of expertise are Angelman Syndrome, Epilepsy, Very Long-Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency, and Seizures.

Their clinical research consists of co-authoring 114 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Prader-Willi Syndrome.

Locations

Tochigi, Japan
Other Locations
Mibu, 3210293, Japan
Sapporo, 0608638, Japan
Chiyoda, 1018643, Japan
Tokyo, 1018643, Japan
0608648, Japan
Chuo, 1040045, Japan
Chiba, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Efficacy and Safety Study of Vatiquinone for the Treatment of Mitochondrial Disease Subjects With Refractory Epilepsy
Efficacy and Safety Study of Vatiquinone for the Treatment of Mitochondrial Disease Subjects With Refractory Epilepsy
Enrollment Status: Terminated
Publish Date: August 27, 2024
Intervention Type: Other, Drug
Study Drug: Vatiquinone
Study Phase: Phase 2/Phase 3
A Phase 3, Multicenter, Open-label Extension Study of Buccally Administered MHOS/SHP615 in Pediatric Patients With Status Epilepticus (Convulsive) in Community Settings
A Phase 3, Multicenter, Open-label Extension Study of Buccally Administered MHOS/SHP615 in Pediatric Patients With Status Epilepticus (Convulsive) in Community Settings
Enrollment Status: Completed
Publish Date: September 14, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Multicenter, Open-label Study to Determine the Efficacy, Safety, and Pharmacokinetics of Buccally Administered MHOS/SHP615 in Pediatric Patients With Status Epilepticus (Convulsive) in the Hospital or Emergency Room
A Phase 3, Multicenter, Open-label Study to Determine the Efficacy, Safety, and Pharmacokinetics of Buccally Administered MHOS/SHP615 in Pediatric Patients With Status Epilepticus (Convulsive) in the Hospital or Emergency Room
Enrollment Status: Completed
Publish Date: July 31, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 2 Less Clinical Trials

114 Total Publications

Macrophage activation syndrome associated with multi-system inflammatory syndrome in children: a case report and cytokine profile.
Macrophage activation syndrome associated with multi-system inflammatory syndrome in children: a case report and cytokine profile.
Journal: Immunological medicine
Published: September 13, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Shiraishi's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 43 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile